SMILES string
N4(CC(C4)C(=O)O)CC1=C(c2c(cc(cc2)OCc3c(cc(cc3)CCC)OC)CC1)C
InChI
1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
InChI key
QDDQIPUKAXBMBX-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Ceralifimod (ONO-4641) is an orally active, potent, S1P1 & S1P5 subtype-selective sphingosine-1-phosphate (S1P) receptor agonist (rat S1P1 Ki = 0.772 nM, human S1P5/1/4 Ki = 0.574/0.626/28.2 nM, hS1P2/3 Ki >5.45 μM against S1P by binding assays) that suppresses forskolin-stimulated cAMP accumulation (IC50 = 27.3 pM/hS1P1, 28.64 pM/rS1P1, 334 pM/hS1P5 using respective transfectants) and induces S1P1 downregulation with a higher potency than SEW2871 & S1P (EC50 = 0.778, 118, 132 nM, respectively). Ceralifimod decreases peripheral blood lymphocytes (EDmax 100 μg/kg po.) in rats, and shows in vivo efficacy in rat and murine EAE models (30 & 100 μg/kg/day po.).
Orally active, potent, S1P1 & S1P5 subtype-selective sphingosine-1-phosphate (S1P) receptor agonist with in vivo efficacy in rat and murine EAE models.
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Takanori Asakura et al.
Mucosal immunology, 11(6), 1606-1620 (2018-08-18)
Sphingolipids play a pivotal role in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, little is known about the precise roles of sphingosine-1-phosphate (S1P), a bioactive sphingolipid metabolite, and its receptor modulation in COPD. In this study, we demonstrated
Haruto Kurata et al.
Journal of medicinal chemistry, 60(23), 9508-9530 (2017-11-10)
The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases
Quality not quantity for transglutaminase antibody 2: the performance of an endomysial and tissue transglutaminase test in screening coeliac disease remains stable over time
Clinical and Experimental Immunology, 171(1), 100-106 (2013)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持